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')1It incidence or diagnostic rate of sclerosing cbolangitis is 
iDCTeasing. Because of the lack of effective medical or surgical 
tberap), for patients "lth end-stage liver disease and sclerosing 
cholangitis, results with orthotopic liver transplantation "'ere 
tUmined. The results of 55 consecutive liver replacements for 
tbis disease "'ere reviewed. The 1- and 2-year actuarial sur-
,hal rates are 71% and 57%, res pecti vel)'. Orthotopic liver 
transplantation for end-stage liver disease from sclerosing 
cbolangitis bas emerged as tbe most effective tberapy. 
SCLEROSING CHOLANGITIS is an enigmatic disease usually found in men younger than 50 years and, 
more often than not, is associated with inflamma-
tory bowel-disease. particularly ulcerative colitis. The 
treatment modalities used for this disease have been as 
\'aried as the descriptions of the disease itself and illus-
trate the dissatisfaction with the currently available 
medical/surgical therapies. Although the histologic 
course of sclerosing cholangitis is considered benign, the 
disease most often takes an indolently malignant course 
and is. in fact. a pernicious disease. Importantly, there is 
an apparent increasillg incidence, or at least an increas-
ing diagnostic rate, of the disease in most developed 
countries. 
We report our experience with hepatic replacement in 
~R patients who had primary sclerosing cholangitis as 
the indication for liver transplantation. We have tried 
(1) to determine the applicability, success rate, and sur-
\ival of orthotopic liver transplantation for patients with 
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primary sclerosing cholangitis, (2) to determine the re-
currence rate of sclerosing cholangitis, should it occur, 
and (3) to assess the course of the associated inflamma-
tory bowel disease under immunosuppression after liver 
transplantation. 
Case Material and Methods 
Between January 1, 1980, and June 30, 1986, 604 
primary orthotopic liver transplants were performed at 
the University of Colorado Health Science Center 
(through 1980), the University Health Center of Pitts-
burgh (since 1981). and the Pittsburgh-affiliated Baylor 
University Medical Center at Dallas (since 1985), All 
patients were treated with combination prednisone-C)-
c1osporine therapy as has been described elsewhere. I- 3 
Patients were considered to have "primary;' sclerosing 
cholangitis4- 7 when there were (1) typical cholangio-
graphic findings of the disease. (2) pathologic confirma-
tion of the disease from the total hepatectomy specimen. 
and (3) the absence of a history or pathologic evidence 
consistent with secondary biliary cirrhosis from other 
causes. 
Fifty-five patients received orthotopic liver transplan-
tation for end-stage primary sclerosing cholangitis. 
Thirty-five were male (63.6%) and twenty were female 
(36.4%). Their ages ranged from 15 to 58 years with a 
median age of 36 years. Only four patients were older 
than 50 years. 
The indications for transplantation were persistent or 
recurrent variceal bleeding in 27.2% (15 of 55 patients), 
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TABLE I, Biliary and Intestinal Operations be/arC' 
Orthotopic Liver Transplantation 
No. of 
Patients 
Hepaticojejunostomy 15 
Cholecystectomy 6 
T-tube drainage orthe choledochus 5 
Cholecystectomy and percutaneous choledochal 
drainage 3 
Choledochoduodenostomy I 
Cholecystojejunostomy I 
Distal splenorenal shunts without prior biliary tract 
surgery 2 
Panial or total abdominal colectomy 4 
Proctocolectomy with ileostomy 3 
Small bowel resection (Crobn's disease) I 
ascending cholangitis in 27.2% (15 of 55 patients), or 
hepatic decompensation, including encephalopathy, co-
agulopathy, anorexia, ascites, fatigue, pruritus, and/or 
3-4+ varices, in 45.5% (25 of 55 patients). Because of 
the risk of cholangiocarcinoma, the timing of transplan-
tation cannot be accurately defined. In general, how-
ever, transplantation is encouraged when the bilirubin 
level exceeds 10 mgjdl or is rapidly rising, when the 
patient's lifestyle has begun to significantly deteriorate, 
or with any suspicion of cholangiocarcinoma. 
Thirty-six (65.4%) of 55 patients had a history of in-
flammatory bowel disease. Thirty-two patients had ul-
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Flo. I. Actuarial survival after orthotopic liver transplantation. 
cerative colitis, and four patients had Crohn's disease 
Cholangiocarcinoma was found in the hepatectolll~ 
specimen of five patients (9%), Three of 55 patients had 
had a carcinoma of the right colon removed by radical 
right colectomy, 11, 4, and 4 years, respectively, befort 
liver transplantation without evidence of recurrence, 
Thirty-one (56.3%) of 55 patients had undergont 
prior biliary tract surgery for diagnosis or treatment of 
the sclerosing cholangitis (Table 1). Fifteen patients had 
undergone hepa\icojejunostomy, six had cholecystec. 
tomy alone, five had T-tube drainage of the choledo.. 
chus, three had cholecystectomy and percutaneous cho.. 
ledochal drainage, one had choledochoduodenostom). 
and one had cholecystojejunostomy. 
Eight patients (14.5%) had undergone prior bowel 
surgery for either inflammatory bowel disease or for 
complicating carcinoma. Three patients had undergont 
partial or total abdominal colectomy. Two of the thret 
patients had proctocolectomy with ileostomy, and ont 
patient had proctocolectomy with an ileoana: 
pull through. A fourth patient had undergone a sma!: 
bowel resection for Crohn's disease. 
The liver disease was diagnosed 1-16 years (mean: 5J 
years) before transplantation, and the bowel disease. 
when present, had existed from 2 to 29 years (mean 
14.8 years). In all but five of the 36 cases with coexistin~ 
inflammatory bowel disease, the bowel disease precedec 
the sclerosing cholangitis. 
Results 
Survival 
As of September I, 1986, there were 37 patients livins 
(67%) and 18 dead (33%) with a mean follow-up perioe 
of 19 months (range: 4-46 months), The actuarial Sur· 
vival rates at 3, 6, 9, 12, 24, and 36 months were 80t:;. 
76%, 76%, 71 %, 57%, and 57%, respectively, calculatec 
by the life table analysis of Kaplan-Meier. (Fig. I). The 
longest surviving patient who had transplantation fo: 
primary sclerosing cholangitis has been observed for 4t 
months. 
Cause of Death 
Eleven patients died within 3 months of transplanta· 
tion, all from direct complications of transplantation or 
the associated immunosuppression. Technical failures . 
primary nonfunction of the graft, infectious complica· :. 
tions, and irreversible acute rejection were the leadin¥ " 
causes of death. Two patients died between 3 and ~ . 
months, one of graft failure and sepsis, and another of :: 
biliary sepsis due to recurrence of cholangiocarcinoma " 
Between 6 and 12 months one patient died of an unrec', 
ognized lymphoproJiferative disorder. Three patients K~ 
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TABLE 2. Causes of Death after Orthotopic Liver Transplantation 
No. of Deaths Cause of Death 
·~~:lhD: I 
radi~ 
. befort 
:nce. 
iergont 
ment Of 
?nts hac! 
ecystec:. 
holedo. 
)US cho. 
ostorn). 
II patients Nine deaths related directly to graft failure: cause of graft failure (including retransplantation) 
(19 transplants) primary nonfunction 7 
technical failure 3 
acute rejection 4 
Two deaths related to immunosupression 
intra·abdominal abscess 
cryptococcal meningitis 
Graft failure and sepsis \.,t. months 
,..1: m(lnths 
1_: ~CPrs 
I patient 
I patient 
I patient 
I patient 
I patient 
I patient 
No deaths 
I patient 
Biliary sepsis and recurrent cholangiocarcinoma 
Unrecognized lymphoproliferative disorder 
Recurrent cholangiocarcinoma 
Systemic fungal infection 
·r boWel 
e or fOr 
dergonc 
he thl'Ct 
lnd Ollt 
leoanaJ 
a small • 
GI bleeding and liver failure from portal vein thrombosis 
t 
ean: 5.8 I 
disease. 
(mean: 
~xistilli 
yreced~ 
:_~ ~tars 
I~ ~Dcars Chronic rejection 
dIed between 1 and 2 years, one of recurrent cholangio-
~rcinomaI one of systemic fungal infection, and the 
(lther of gastrointestinal bleeding and liver failure due to 
rcthrombosis of the portal and superior mesenteric veins 
"hich had been opened with thrombophlebectomy at 
the time of transplantation. No patient died between 2 
and 3 years after transplantation. One patient died of 
h\er failure due to chronic rejection more than 3 years 
afkr transplantation (Table 2). 
!'l1fClogni=ed Cho/angiocarcinoma 
Pre\'iously unrecognized cholangiocarcinoma was 
ts livin~ found in the surgical specimen Qftive of the 55 patients. 
:) period.. There were three women and tw6 men with an average 
rial sur· I age of 35.4 years (range: 24-37 years). Two patients had 
:re 8{)1i. no history of inflammatory bowel disease; three had had 
Jculatedulcerati\e colitis for 16; 20. and 29 years. The patient 
~FK The ; .who had had ulcerativ~ colitis for 16 years had under-
tlOn for· I!one a right colectomy 4 years before liver transplanta-
d for 46 ~ tion for a Duke's B carcinoma of the colon with no 
~y idence of recurrence. The clinically evident liver dis-
~gpC in this subset of patients had been present I. 2.4, 7, 
and 14 years. clearly illustrating that longstanding liver 
dlscase is not a prerequisite for the development of chol-
splanta· angiocarcinoma. Two of these patients died as a result of 
at!on or i recurrent cholangiocarcinoma 4 and 12 months after 
fallures..! transplantation. Three patients are alive, but the follow-
,mplica- i up period is short. The first patient still living is I year 
leading post·transplantation, received adjunctive chemotherapy 
1 and 6 and radiotherapy, but has recurrence of disease. The 
other of rrmaining two patients are 3 months post-transplant 
:inoma. \ without evidence of recurrence: both have undergone 
1 uncec-. radiotherapy and one will undergo chemotherapy as 
patients· "·ell. 
Inflammatory Bowel Disease after Liver Transplanta-
tion 
During the obsen'ation period of 4 months to 4 years, 
nine (34.5%) of 26 patients who had had inflammatory 
bowel disease before transplantation and who survived 
more than 3 months after transplantation developed 
reactivation or exacerbation of the bowel disease. How-
ever, the recurrent inflammatory bowel disease was 
minimally symptomatic in seven of the nine patients, 
requiring only short-term treatment with sulfasalazine, 
and was moderate in two of nine patients, requiring 
long-term sulfasalazine therapy and increased doses of 
steroids. 
Annual or semiannual colonoscopic examinations of 
the surviving patients have not detected any colorectal 
malignancy during this relatively short period of obser-
vation, but in none of the patients \\ith pre-existing ab-
normalities have the colonoscopic findings become to-
tally normal. It is also noteworthy that none of the pa-
tients without a pre-existing history of inflammatory 
bowel disease has developed it after transplantation. 
Recurrence of Sclerosing Cholangitis 
In one patient. chemical and radiological abnormali-
ties developed in the graft compatible with sclerosing 
cholangitis I year after transplantation (Fig. 2A), but the 
abnormalities have been stable for the ensuing year. 
Four patients whose original liver disease was not scle-
rosing cholangitis also had similar abnormalities de-
velop after histologically proven graft rejection (Fig. 2B). 
Discussion 
Primary sclerosing cholangitis remains a disease of 
unknown cause. It has become the third most common 
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FIGs. 2A and B. A. Cholangiogram showing changes of sclerosing 
cholangitis I year after transplantation. The original diagnosis was 
sclerosing cholangitis. B. Cholangiogram showing changes of scleros-
ing cholangitis in a patient with a >90% stenosis of the hepatic artery 
and after multiple biopsy-proven rejections. The original diagnosis was 
chronic active non-A. non-B hepatitis. 
indication for orthotopic liver transplantation in adults. :he 
the first being post necrotic cirrhosis and the second 
being primary biliary cirrhosis. Treatment has been at. ~igK 
tempted with steroids, cholestyramine, azathioprine, D. 
penicillamine,8 choledochoenteric anastomoses,9 and 
choledochal drainage by T -tube or pilastic~ transhepatic 
stents. JO 
-.\ 
Wiesner and LaRusso, II have reported the largest 
group of patients with primary sclerosing cholangitis JJ : 
treated without trdnsplantation at a single institution 
Thirty-nine (78%) of their 50 patients had adequate fol. 
low-up for presentation. Thirteen (33%) of the 39 pa. 
tients were dead ~fter a mean interval of 57 months after 
diagnosis. At the time of reporting, 26 patients ESS~g 
were alive, but 12 had end-stage liver disease. Thus, an 
unsatisfactory result had been obtained in at least S4~ 
2 
3 
of the cases. 
Cameron et aI., JO have reported the operative place-
ment of Silastic transhepatic stents in a group of 11 
patients. Eleven of the original 22 patients were not se· 
lected for operation, and of those operated on the major-
ity have either died or come to transplantation, includ· 
ing three patients treated by us. The prior performance 
of this type of operation has made transplantation ex-
ceptionally difficult. 
The fact that a satisfactory result could be obtained in 
two thirds of the 55 patients herein reported after a 
mean follow-up of more than 1.5 years is encouraging. 
All patients were medical/surgical treatment failures 
with liver disease that preceded the transplantation by a 
mean of 68 months. Even though 14 patients diedln less 
than 1 year, the 71 % actuarial I-year survival and the 
57% 2-year survival rates are not significantly different 
than that of the overall group of 604 patients of our toti 
senes. 
Cholangiocarcinoma was found at pathologic exami· 
nation of the removed liver specimen in five (9.990) of 
55 patients. Two of these recipients have died and one 
has recurrence of disease. Although two patients are stil! 
disease free, their long-term outlook remains to be de· I 
termined since the follow-up period has been short. We 
currently believe that any patient undergoing stenting 0: I 
the biliary tree should have brushings. cytologic examl' i 
nation, and/or needle biopsies obtained in an attempt lc I 
bring these patients to earlier transplantation before rna· i 
lignant changes occur. 
This experience demonstrates the effectiveness 0: 
orthotopic liver transplantation for patients with ad-
vanced primary sclerosing cholangitis. In the future. 
liver replacement should not be reserved as a last minute 
operation for moribund patients who have undergoot 
the gamut of palliative medical and surgical therapies 
that have not been shown to be effective in prolongin, 
life or reducing morbidity. Specifically, palliative opera-
tions such as choledochoenterostomy for sc1erosio( 
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. 's should be avoided since the same results can 
• KIIEtr:ln!l~~d by transhepatic biliary drainage and balloon 
r< tDDDt~~n or by endoscopic procedures, particularly in 
ddgtg~atients whose sclerosing ch~lan~Ktis is limited. to a 
dl~" segment of the extrahepatIc blhary tree. With a 
~~ar survival rate of 57%, orthotopic liver transplanta-
• 'n has emerged as the sole form of therapy that offers 
"-'. . lientS who had faIled treatment a chance at returnmg 
J'ol normalcy at the cost of the least number of lives. 
t" 
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